Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075621 · ClinicalTrials.gov registry record · Phase 2
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
A Phase 2 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00075621 is a Phase 2 study that has completed, run by Boston Medical Center. The registered enrollment target is 62 participants.
The verdict
NCT00075621, a Phase 2 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
RATIONALE: Autologous stem cell transplantation may be effective treatment for primary systemic (AL) amyloidosis. PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell transplantation works in treating patients with primary systemic (AL) amyloidosis.
Interventions
- DRUG melphalan
- DRUG filgrastim
- PROCEDURE autologous peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2000-08 |
| Est. Completion | 2020-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075621
The ClinicalTrials.gov registry entry for NCT00075621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00075621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075621 about?
NCT00075621 is a clinical study titled "Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis". RATIONALE: Autologous stem cell transplantation may be effective treatment for primary systemic (AL) amyloidosis. PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell transplantation works in treating patients with primary systemic (AL) amyloidosis.
What is the current status of trial NCT00075621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2000-08. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT00075621?
The interventions under investigation include: melphalan (DRUG), filgrastim (DRUG), autologous peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00075621?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.